Samrat Pharmachem Limited (BOM:530125)
India · Delayed Price · Currency is INR 260.40
+5.40 (2.12%)
At close: Nov 13, 2026
Samrat Pharmachem Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 805 | 602 | 966 | 1,030 | 1,147 | 1,498 | |
Market Cap Growth | -5.72% | -37.67% | -6.21% | -10.15% | -23.45% | 256.47% |
Enterprise Value | 848 | 518 | 986 | 1,227 | 1,324 | 1,530 |
Last Close Price | 260.40 | 194.95 | 311.79 | 331.90 | 368.45 | 480.90 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | - | - | 13.59 | 47.64 | 6.89 | 8.72 |
PS Ratio | 0.27 | 0.21 | 0.34 | 0.37 | 0.37 | 0.68 |
PB Ratio | 1.18 | 0.88 | 1.35 | 1.59 | 1.82 | 3.20 |
P/TBV Ratio | 1.18 | 0.88 | 1.35 | 1.59 | 1.82 | 3.20 |
P/FCF Ratio | 13.91 | 10.41 | - | 11.78 | - | 9.25 |
P/OCF Ratio | 9.06 | 6.78 | - | 10.95 | - | 8.57 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 0.29 | 0.18 | 0.35 | 0.44 | 0.43 | 0.69 |
EV/EBITDA Ratio | - | - | 9.47 | 48.85 | 5.51 | 6.28 |
EV/EBIT Ratio | - | - | 10.11 | 65.76 | 5.66 | 6.43 |
EV/FCF Ratio | 14.66 | 8.96 | - | 14.03 | - | 9.45 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.16 | 0.16 | 0.14 | 0.13 | 0.30 | 0.16 |
Debt / EBITDA Ratio | - | - | 0.95 | 3.37 | 0.78 | 0.31 |
Debt / FCF Ratio | - | 1.85 | - | 0.97 | - | 0.46 |
Net Debt / Equity Ratio | 0.06 | 0.07 | 0.13 | -0.02 | 0.11 | -0.15 |
Net Debt / EBITDA Ratio | -3.18 | -2.17 | 0.91 | -0.49 | 0.28 | -0.29 |
Net Debt / FCF Ratio | - | 0.77 | -0.90 | -0.14 | -0.62 | -0.44 |
Asset Turnover | - | 2.36 | 2.35 | 2.36 | 3.09 | 3.13 |
Inventory Turnover | - | 6.94 | 9.09 | 10.16 | 12.37 | 15.95 |
Quick Ratio | - | 1.03 | 1.15 | 1.40 | 1.20 | 1.56 |
Current Ratio | - | 1.86 | 2.09 | 1.82 | 1.86 | 1.91 |
Return on Equity (ROE) | - | -4.73% | 10.40% | 3.38% | 30.25% | 44.95% |
Return on Assets (ROA) | - | -1.41% | 5.01% | 0.98% | 14.53% | 20.93% |
Return on Invested Capital (ROIC) | -2.90% | -3.60% | 9.67% | 2.40% | 31.51% | 45.83% |
Return on Capital Employed (ROCE) | - | -4.00% | 13.60% | 2.90% | 36.90% | 50.30% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 12, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | -2.75% | -5.50% | 7.36% | 2.10% | 14.50% | 11.47% |
FCF Yield | 7.19% | 9.60% | -10.97% | 8.49% | -9.50% | 10.81% |
Dividend Yield | 0.38% | - | 0.32% | 0.30% | 0.27% | 0.21% |
Payout Ratio | - | - | 4.35% | 14.29% | 1.86% | - |
Total Shareholder Return | 0.50% | - | 0.32% | 0.30% | 0.27% | 0.21% |